ArticleFrontiers in human neuroscience2025
Rising burden of subarachnoid hemorrhage linked to high systolic blood pressure among young and middle-aged populations: temporal trends and global implication.
Article in Frontiers in human neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Subarachnoid hemorrhage: epidemiology, risk factors, pathogenesis, and clinical therapies.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Subarachnoid hemorrhage (SAH) is a devastating cerebrovascular event that leads to high mortality and long-term disability, particularly among adults aged 25-49 years. Elevated systolic blood pressure (SBP) is the leading modifiable risk factor, yet its global burden in this age group has not been systematically assessed. Methods: We analyzed population-level epidemiological data across 204 countries and territories from 1990 to 2021 to estimate SAH mortality and disability-adjusted life-years (DALYs) attributable to high SBP. Temporal trends were evaluated using estimated annual percentage change (EAPC), and future trajectories to 2050 were projected with autoregressive integrated moving average (ARIMA) models. Results: Globally, SAH caused 24,908 deaths and 1,373,366 DALYs in 2021 due to high SBP in adults aged 25-49 years. Males had higher rates than females (mortality: 0.78 vs. 0.48 per 100,000; DALYs: 42.4 vs. 27.0 per 100,000), though females experienced steeper declines (EAPC_mortality: -1.78%). The highest burden was in the 45-49 age group (deaths: 9,768; DALYs: 474,092). From 1990 to 2021, high-SDI regions achieved the greatest reductions in mortality (-50.3%) and DALYs (-46.8%), while low-SDI regions saw increases in deaths (+109.5%) and DALYs (+114.7%). Nationally, Zimbabwe and Guatemala showed the sharpest increases in mortality (EAPC: +4.71% and +3.76%), while Sweden and Swiss Confederation achieved the greatest declines (EAPC: -5.5% and -4.9%). Forecasts suggest continued global declines by 2050, but widening disparities by sex, age, and socio-demographic status. Conclusion: Although the global burden of SAH attributable to high SBP is decreasing, young and middle-aged adults-especially males and those in low-SDI regions-continue to face substantial risks. Targeted hypertension control and region-specific prevention strategies are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.